|1.||Colombo, Diego: 5 articles (05/2011 - 12/2002)|
|2.||Toma, Lucio: 4 articles (12/2006 - 12/2002)|
|3.||Nishino, Hoyoku: 4 articles (12/2006 - 12/2002)|
|4.||Tokuda, Harukuni: 4 articles (12/2006 - 12/2002)|
|5.||Ronchetti, Fiamma: 4 articles (12/2006 - 12/2002)|
|6.||Franchini, Laura: 3 articles (05/2011 - 01/2005)|
|7.||Takayasu, Junko: 2 articles (12/2006 - 12/2002)|
|8.||Scala, Antonio: 2 articles (03/2003 - 12/2002)|
|9.||Erdmann, Frank: 1 article (06/2015)|
|10.||Schmidt, Matthias: 1 article (06/2015)|
05/01/2011 - "Thus, these results reveal the role of a PKC-dependent mechanism in glycoglycerolipid analogues mediated protective effects and highlight their possible employment in the field of prevention/treatment of cancer."
05/01/2011 - "Glycoglycerolipid analogues, derived from 2-O-β-D-galactosylglycerol, have been synthesized on the base of the structure of natural glycoglycerolipids showing anti-tumor and anti-inflammatory efficacy. "
12/01/2006 - "All compounds were active in inhibiting the EBV activation promoted by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), the branched compounds resulting in the most active glycoglycerolipid analogues of the series. "
12/01/2002 - "Nine new synthetic compounds, structurally related to the most active glycoglycerolipid analogues carrying a hexanoyl chain, were tested for their anti-tumor-promoting activity using a short-term in vitro assay for Epstein-Barr virus (EBV) activation. "
12/20/2000 - "Anti-tumor-promoting effects of glycoglycerolipid analogues on two-stage mouse skin carcinogenesis."
|2.||Glioblastoma (Glioblastoma Multiforme)
05/01/2011 - "In addition, the branched glycoglycerolipid (compound 2) was able to inhibit PKC translocation and activation in naturally highly PKC activating glioblastoma cells, U87MG. "
05/01/2011 - "Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG."
|3.||DNA (Deoxyribonucleic Acid)